Takeda buys Ariad Pharmaceuticals for $ 5.2 billion

The highly strategic deal will transform Takeda’s global oncology portfolio and pipeline by expanding into solid tumours and reinforcing its existing strength in haematology. 

The acquisition of Ariad brings two innovative targeted therapies that will expand and enhance Takeda’s existing oncology portfolio. Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cell lung cancer (NSCLC). The addition of Iclusig will broaden Takeda’s strong haematology franchise to include chronic myeloid leukaemia (CML) and a subset of acute lymphoblastic leukaemia (ALL). Together, these two innovative targeted therapies will position Takeda for sustainable long-term growth in oncology.

Takeda’s track record of successful oncology product launches - Adcetris (brentuximab vedotin), Ninlarotm (ixazomib) and Velcade (bortezomib) - means it has the experience and expertise required to deliver the successful launch of brigatinib and to ensure that it achieves global reach.

Ariad provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets.

Iclusig, a commercialised therapy with continued strong sales growth potential, delivers immediate value. Brigatinib, an investigational drug product with peak annual sales potential of over $1 billion, will generate significant long-term value for Takeda. US approval is expected in the first half of 2017 with global filing thereafter. Beyond Iclusig and brigatinib, Ariad’s commitment and expertise in targeted kinase inhibition linked to strong translational science generated further pipeline opportunities which provide additional long-term upside potential.

Takeda will leverage Ariad’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget.